🇺🇸 FDA
Pipeline program

-, -, PACLITAXEL , MK-2870, -, MK-1022, RAMUCIRUMAB , MK-2870, PARACETAMOL

MK-3475-06D

Phase 2 small_molecule active

Quick answer

-, -, PACLITAXEL , MK-2870, -, MK-1022, RAMUCIRUMAB , MK-2870, PARACETAMOL for Gastroesophageal cancer is a Phase 2 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).

Program details

Company
Merck Sharp and Dohme
Indication
Gastroesophageal cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials